The Efficacy and Safety of Neurokinin 3 Receptor Antagonists for Vasomotor Symptoms in Menopausal Women: A Systematic Review and Meta-Analysis
ASIAN JOURNAL OF FERTILITY ENDOCRINOLOGY AND REPRODUCTION · 2026
DOI: 10.66060/ajfer.v1i1.12 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift ASIAN JOURNAL OF FERTILITY ENDOCRINOLOGY AND REPRODUCTION, 2026. Verfasst von Najwa Nidaul Fitroh und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Vasomotor symptoms (VMS) are the most common and disruptive menopausal complaints, impairing sleep, daily functioning, and quality of life. Limitations of hormonal therapy and modest benefit of current non-hormonal options underscore the need for targeted alternatives. Neurokinin-3 receptor (NK3R) antagonists represent a novel non-hormonal therapy that modulates hypothalamic KNDy neuron dysregulation linked to estrogen decline. This study aimed to evaluate the efficacy and safety of NK3R antagonists in menopausal women with VMS.
Methods
A systematic review and meta-analysis were conducted following PRISMA guidelines. Searches across PubMed, Cochrane, ScienceDirect, Epistemonikos, Scopus, ProQuest, and EBSCO through November 2025 identified clinical trials assessing NK3R antagonists for VMS. Independent reviewers performed data extraction and risk-of-bias assessment using the Cochrane RoB 2.0 tool. Pooled analyses were calculated using standardized mean differences (SMDs) or odds ratios (ORs) with 95% confidence intervals.
Results
Sixteen clinical trials met the inclusion criteria. NK3R antagonists significantly improved menopause-specific quality of life (SMD −0.46; 95% CI −0.67 to −0.25), PROMIS sleep-related outcomes (SMD −0.23; 95% CI −0.32 to −0.13), and work productivity (SMD −0.52; 95% CI −0.97 to −0.06). Patients were more likely to report meaningful improvement on PGI-C (OR 6.34; 95% CI 1.25–32.00). Adverse event rates were comparable to placebo (OR 0.84; 95% CI 0.36–1.93), with most events mild and transient.
Conclusion
NK3R antagonists effectively reduce vasomotor symptoms and improve quality of life with a safety profile similar to placebo. These findings support NK3R antagonists as a valuable non-hormonal therapeutic option, particularly for women unable or unwilling to use hormonal therapy.
Zitieren
APA
Fitroh, N. N., Mufidah, A. R., Zalika, R. A., & Ningrum, L. D. R. (2026). The Efficacy and Safety of Neurokinin 3 Receptor Antagonists for Vasomotor Symptoms in Menopausal Women: A Systematic Review and Meta-Analysis. ASIAN JOURNAL OF FERTILITY ENDOCRINOLOGY AND REPRODUCTION. https://doi.org/10.66060/ajfer.v1i1.12
Vancouver
Fitroh NN, Mufidah AR, Zalika RA, Ningrum LDR. The Efficacy and Safety of Neurokinin 3 Receptor Antagonists for Vasomotor Symptoms in Menopausal Women: A Systematic Review and Meta-Analysis. ASIAN JOURNAL OF FERTILITY ENDOCRINOLOGY AND REPRODUCTION. 2026. doi:10.66060/ajfer.v1i1.12
BibTeX
@article{Fitroh2026,
author = {Fitroh, Najwa Nidaul and Mufidah, Aliyah Redya and Zalika, Regina Amanda and Ningrum, Latifah Dwi Ratna},
title = {The Efficacy and Safety of Neurokinin 3 Receptor Antagonists for Vasomotor Symptoms in Menopausal Women: A Systematic Review and Meta-Analysis},
journal = {ASIAN JOURNAL OF FERTILITY ENDOCRINOLOGY AND REPRODUCTION},
year = {2026},
doi = {10.66060/ajfer.v1i1.12}
}
EUVIMED